. Author manuscript; available in PMC: 2022 Apr 1.

Published in final edited form as: Curr Hematol Malig Rep. 2021 Mar 17;16(2):183–191. doi: 10.1007/s11899-021-00624-6

Table 1:

Selected Monoclonal Antibodies Investigated in Clinical Trials in Multiple Myeloma

Agent	Target	Clinical Trial	Phase	Single vs combination
CJM112	IL-17	NCT03111992	I	Single/combination (Anti-PD1 or SMAC-mimetic)
BHQ880	DKK-1	NCT01302886, NCT01337752	II	Single/combination (bor and dex)
Lirilumab	KIR	NCT02252263	I	With elotuzumab
MOR202/TJ202	CD38	NCT01421186	I/II	With dex and len/pom
		NCT03860038	II	With dex
		NCT03952091	III	With len and dex
TAK-079	CD38	NCT03439280	I/II	Single/combination (pom/dex)
TAK-573	CD38	NCT03215030	I/II	Single (phase I) With dex (phase II)
SEA-BCMA	BCMA	NCT03582033	I	With dex

Bor: bortezomib, len: lenalidomide, pom: pomalidomide, dex: dexamethasone